The global canine influenza vaccine market comprises vaccines that offers protection against canine influenza virus strains (CIV), a contagious respiratory disease affecting dogs. Canine influenza, commonly known as dog flu, is a contagious viral illness that infects the upper respiratory tract of dogs. It is caused by H3N8 strains of the influenza virus. Canine influenza vaccines work by stimulating a dog's immune system to recognize and defend against CIV strains.

The Global Canine Influenza Vaccine Market is estimated to be valued at US$ 1,805.7 Mn in 2024 and is expected to exhibit a CAGR of 5.1% over the forecast period 2024 to 2031.

Key Takeaways

There is a growing demand for Global Canine Influenza Vaccine Market Sizefrom pet clinics, animal hospitals, and veterinary practices due to increasing pet ownership and awareness about pet health, disease prevention, and vaccination. According to the American Pet Products Association (APPA), around 90 million dogs are owned as pets in the United States alone.

Key players operating in the global canine influenza vaccine market are Zoetis Services LLC, Merck Co., Inc., Covetrus, CSL Limited, Boehringer Ingelheim Animal Health USA Inc., and Elanco. Zoetis Services LLC leads the market with its recommended CIV vaccine Prodigest.

Geographically, North America dominates the global canine influenza vaccine market due to high pet adoption rates and rising pet healthcare expenditure. Manufacturers are also increasingly focusing on expanding their presence in emerging markets like Asia Pacific and Latin America through strategic collaborations.

Get More Insights On Global Canine Influenza Vaccine Market